TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03278145

Intervention type: GENETIC
Intervention: Genetic analyses
Description: Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
Study: NCT02797535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy procedures
Description: GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
Study: NCT03874403

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DSA
Description: The changes on DSA on NIVATS and VATS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA
Description: The changes on DSA on NIVATS and VATS
Study: NCT04286958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
Study: NCT01028053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutemetamol (18F) Injection
Description: All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
Study: NCT02632214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI measure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: fMRI measure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI measure
Study: NCT03346512

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Cardiac surgery
Study: NCT02549378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal microscopy
Description: microvessel diameter measured by confocal microscopy
Study: NCT02537925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg bid po, to the end of concurrent radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Radiotherapy
Description: The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Radiotherapy
Description: The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
Study: NCT03181009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
Study: NCT04526587

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patient's electronic health records are reviewed
Study: NCT03181009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food Flour Allergens
Description: The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food Flour Allergens
Description: The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
Study: NCT03943992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 40mg
Description: Patients should take druges 30 minutes before breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40mg
Description: Patients should take druges 30 minutes before breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Study: NCT03428269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation by gaming (LabForGames Warning)
Description: comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional education
Description: comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
Study: NCT04124510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name: Flutiform K-haler
Description: Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
Study: NCT01346553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESVV device
Description: wearing the ESVV device for 6 hours
Study: NCT02714959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Study: NCT01168479

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLAME boost
Description: In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard arm
Description: The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
Study: NCT04688996

Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral Flow Assay for Pathogens of the Plague
Description: A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
Study: NCT02260011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide HFA-134a inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide HFA-134a inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent® CFC inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent® CFC inhalation aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02106208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA diet
Study: NCT00003018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyridamole
Description: 75mg/dose, PO, Days 1-28 of 5 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
Study: NCT04927650

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV testing
Description: Undergo collection of cervical samples for HPV testing

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01264315

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart.
Study: NCT00919022

Intervention type: DRUG
Intervention: Cyproterone Acetate (Androcur, BAY94-8367)
Description: Patients in regular clinical practice receiving Androcur according to local drug information
Study: NCT04163198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation
Description: Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exsufflation
Description: Patients will receive different exsufflation pressures at fixed insufflation pressure.
Study: NCT02773628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acar'up system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acar'up placebo system
Study: NCT02255279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)
Description: A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
Description: A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
Study: NCT04140929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health Tool Box
Description: Please see, description of the intervention group
Study: NCT00509600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 0.8 mg/kg Subcutaneously Once A Week for 90 Days
Study: NCT01239745

Intervention type: DRUG
Intervention: Aromasin
Description: Aromasin® one 25 mg tablet to be taken once daily
Study: NCT00249041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Etanercept
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel liquid
Description: 50 mg Etanercept liquid injected SC once weekly using prefilled syringes
Study: NCT03004092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Twice weekly blood sample, and at every outpatient visit
Study: NCT03518840

Intervention type: DEVICE
Group type: OTHER
Intervention: SIJ Belt
Description: Support Belts
Study: NCT00357604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)
Description: Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Description: Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
Study: NCT01229553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decolonization
Description: The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
Study: NCT02320825

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high-dose hypofractionated SRS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures
Study: NCT05160285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 100 MG in 10 ML Injection
Description: If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
Study: NCT02898441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography
Description: LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
Study: NCT00950092

Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris-AF Tethered Coagulation System with VisiTrax
Description: Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
Study: NCT00929097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation aids
Description: * Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Dissemination of guidelines
Study: NCT00090402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Fish oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic Acid
Description: Lipoic acid capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil Placebo
Description: Soybean oil placebo capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoic Acid Placebo
Description: Lipoic acid (LA) placebo capsule containing no LA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lipoic Acid Placebo
Description: Lipoic acid (LA) placebo capsule containing no LA
Study: NCT01893788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren: 150 to 300 mg daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 50 to 100 mg daily for 48 weeks
Study: NCT01207544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitball exercise
Description: Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented motor training program
Description: Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
Study: NCT04244045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital muscle inhibition
Description: The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition
Description: The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition
Description: The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot
Study: NCT00710970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
Study: NCT00961012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Big Squeeze
Description: Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
Study: NCT03043937

Intervention type: OTHER
Intervention: registry

Intervention type: OTHER
Intervention: registry
Study: NCT02645708

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retrograde Intrarenal Surgery
Description: Patients undergo Retrograde Intrarenal Surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EPVL after RIRS
Description: Patients in Group 2 undergo EPVL after RIRS
Study: NCT02677285

Intervention type: OTHER
Intervention: Different type of wound

Intervention type: OTHER
Intervention: Different type of wound
Study: NCT02391584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XprESS
Description: Balloon dilation of the Eustachian tube

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Continued medical management